DPX-Survivac and Pembrolizumab Trial
Phase 2
102
about 3.9 years
18+
17 sites in CA, FL, GA +8
What this study is about
Researchers are testing DPX-Survivac, pembrolizumab, with or without low-dose cyclophosphamide (CPA), in people with relapsed or refractory diffuse large B-cell lymphoma. The trial will last for about 1412 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CPA
- 2.Take DPX-Survivac
- 3.Take Pembrolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Objective response rate (ORR) in each of the study arms
Secondary: Changes in Patient Reported Outcomes using the EQ-5D-5L Assessment, Changes in Patient Reported Outcomes using the FACT-Lym Assessment, Complete response (CR) rate in each of the study arms, Disease control rate (DCR) in each of the study arms, Duration of response (DOR) in each of the study arms, Progression-Free Survival in each of the study arms, Rate of Adverse Events using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in each of the study arms
Oncology